Trazpiroben

Trazpiroben
Clinical data
Other names	TAK-906; ATC-1906
Drug class	Dopamine antagonist
Identifiers
	IUPAC name 3-[[1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoic acid;
CAS Number	1352993-39-5;
PubChem CID	54768846;
ChemSpider	81367274;
UNII	FH87H57Q4Y;
ChEMBL	ChEMBL4650340;
Chemical and physical data
Formula	C31H39N3O4
Molar mass	517.670 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCC(CC1)N2CN(C(=O)C23CCN(CC3)CCCC(=O)C4=CC=CC=C4)CC5=CC(=CC=C5)C(=O)O;
	InChI InChI=1S/C31H39N3O4/c35-28(25-10-3-1-4-11-25)15-8-18-32-19-16-31(17-20-32)30(38)33(23-34(31)27-13-5-2-6-14-27)22-24-9-7-12-26(21-24)29(36)37/h1,3-4,7,9-12,21,27H,2,5-6,8,13-20,22-23H2,(H,36,37); Key:BDXJYAAYLZTLEK-UHFFFAOYSA-N;

Trazpiroben (developmental code name TAK-906) is a dopamine antagonist drug which was under development for the treatment of gastroparesis.^[1]^[2]^[3]^[4]^[5] It acts as a peripherally selective dopamine D₂ and D₃ receptor antagonist.^[1]^[2] The drug has been found to strongly increase prolactin levels in humans, similarly to other peripherally selective D₂ receptor antagonists like domperidone.^[5] Clinical development of trazpiroben was discontinued before April 2022.^[1] Trazpiroben was originated by Altos Therapeutics and was under development by Takeda Oncology.^[1]

Other namesTAK-906; ATC-1906

Quick facts Clinical data, Other names ...

Close

References